Researchers have long suspected that PMDD symptoms arise because the brain responds differently to natural hormone changes across the menstrual cycle. This study provides new evidence for one specific piece of that puzzle: a receptor in the brain called the GABAA receptor, which helps regulate mood and emotional responses.
The study followed 29 women with PMDD and 27 women without the condition, testing them during both their symptom-free follicular phase and their symptomatic luteal (premenstrual) phase. The researchers measured gene activity for specific parts of the GABAA receptor in immune cells from blood samples, and also used brain scanning to look at emotional responses in the amygdala — a brain region involved in generating emotions.
The key finding was that women with PMDD showed a drop in activity of the "delta subunit" gene during their luteal phase. This particular subunit is important because it makes the GABAA receptor especially responsive to allopregnanolone, a calming brain chemical produced from progesterone. When this subunit's activity was lower, women with PMDD also showed stronger emotional reactions in their amygdala during the luteal phase. Women without PMDD did not show these patterns.
This matters because it suggests that in PMDD, the brain may struggle to properly adjust these mood-regulating receptors when hormone levels shift after ovulation. The inability to adapt could help explain why emotional symptoms flare during the premenstrual window. While this is early-stage research with a small sample, and blood cell measurements may not perfectly mirror what happens in the brain, it points toward a specific biological mechanism that could eventually lead to more targeted treatments for PMDD.
Key findings
- Women with PMDD had significantly lower delta GABAA receptor subunit mRNA expression in PBMCs during the luteal phase compared to the follicular phase (ANCOVA interaction: F(1,40)=5.67, p=0.02, η²=0.02; post-hoc padj=0.004)
- Lower delta subunit mRNA expression in PMDD women was associated with higher emotion-related amygdala activation during the luteal phase (p=0.04)
- Beta-2 subunit mRNA expression was also lower in the luteal versus follicular phase in PMDD women (ANCOVA phase effect: F(1,32)=4.377, p=0.04, η²=0.034; post-hoc padj=0.01)
- Control women showed increased beta-3 subunit mRNA expression in the luteal compared to follicular phase (padj=0.04), a pattern not seen in PMDD
- No significant correlations were found between serum neurosteroid levels (ALLO, ISO, ISO/ALLO ratio) and GABAA subunit mRNA expression in either group
- Alpha-1, alpha-4, alpha-5, and gamma-2 subunit mRNAs were undetectable in the majority of PBMC samples
Methods, briefly
Cross-sectional repeated-measures design with N=29 women with PMDD and N=27 asymptomatic controls. PMDD was diagnosed using prospective daily symptom ratings (DRSP) over at least two menstrual cycles. Participants were tested in both mid-follicular (days +5 to +11) and late-luteal (days -8 to -1) phases. GABAA receptor subunit mRNA (α1, α4, α5, β2, β3, γ2, δ) was quantified in PBMCs using RT-qPCR. Serum ALLO and ISO were measured by UPLC-MS/MS. fMRI with an emotional face-matching task was used to measure amygdala reactivity. Two-way repeated measures ANCOVAs controlled for psychiatric history.
Limitations to keep in mind
- mRNA expression in peripheral blood cells may not directly reflect GABAA receptor subunit expression in the brain
- mRNA levels do not necessarily correspond to functional protein levels due to post-translational mechanisms
- Low mRNA levels required many PCR cycles (>35) for detection, leading to high variability and many undetectable subunits
- Mood symptom ratings were averaged from screening cycles rather than collected on actual scanning days
- Small sample size (N=56 total) limits statistical power
- Single-center study
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.